Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer

Typically, this syndrome requires moderate baseline analgesia with increased on-demand doses. Other techniques for treating bone pain, including radiation therapy, neuraxial application of analgesics, nerve blocks and local stabilisation procedures, should be considered. In addition, therapy with bisphosphonates targeting bone-specific pain is an important strategy. This review discusses the various management options for bone pain arising from metastatic bone disease.

Section: Breast Cancermentioning

confidence: 82%

Metastatic bone pain: treatment options with an emphasis on bisphosphonates

Moos

Strasser

Gillessen

et al. 2008

“…6 Long-term effect of oral ibandronate on pain score in patients with breast cancer [2] Fig. 5 Long-term effect of intravenous ibandronate on quality of life parameters in patients with breast cancer [6] …”

Section: Discussionmentioning

confidence: 99%

Effectiveness of bisphosphonates on bone pain and quality of life in breast cancer patients with metastatic bone disease: a review

Diel

2007

“…Horizontal lines represent the standard error. Adapted with permission from Eastham et al [26] emotional, and social functioning subscales and the global health score of the EORTC QLQ-C30 (P<.05 for all) in patients with bone metastases from breast cancer (N=466) [25]. In a smaller open-label trial among patients with bone metastases from prostate cancer treated with IV ibandronate (N=25), the mean baseline Karnofsky index of 55% increased to 80%, although the time point for the improved index was not noted [35].…”

Section: Mobility and Functional Independencementioning

confidence: 99%

Impact of skeletal complications on patients’ quality of life, mobility, and functional independence

Costa

Badı́a²,

Chow

et al. 2008

182

133

Pathologic fractures often require surgical intervention and palliative radiotherapy. Thus, patients suffer impaired mobility, loss of functional independence, and diminished health-related quality of life (HRQOL). Bisphosphonates can delay the onset and reduce the incidence of SREs and have become the standard of care for the treatment of malignant bone disease; however, minimal information on the effects of bisphosphonate treatment on HRQOL is available. Targeted HRQOL assessments for patients with malignant bone disease are currently under development and are discussed herein.